RxDoctor Payments Data

Rabin Niroula

Internal Medicine · Worcester, MANPI 1255561551

Payments from drug & device makers

$454,411in general payments, 2019–2025

Across 46 payments — averaging $9878.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$249K
  • Bristol Myers Squibb$76K
  • E.r. Squibb & Sons, L.L.C.$72K
  • Takeda Pharmaceuticals U.S.A., Inc.$51K
  • Johnson & Johnson$3K
  • Janssen Scientific Affairs, LLC$2K
  • plus $366 from 3 others

What the payments were for

  • Consulting fees$5,26391%
  • Food & beverage$2975%
  • Education$1983%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$454,411 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$40,754
Medicare patients
203
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide144$1,611,662
VenclextaVenetoclax100$719,036
PomalystPomalidomide28$626,060
JakafiRuxolitinib Phosphate33$550,071
RevlimidLenalidomide32$526,237
CalquenceAcalabrutinib Maleate35$432,075
IclusigPonatinib Hcl16$335,538
SprycelDasatinib18$242,118
GleevecImatinib Mesylate13$108,786
Imatinib Mesylate38$49,534
EliquisApixaban34$25,635
ValacyclovirValacyclovir Hcl91$3,748
Hydroxyurea57$1,555
Mirtazapine34$510
Dexamethasone41$414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$72,355$868,17946 claims
Incyte CorporationJakafi$166$550,07133 claims
Bristol Myers SquibbRevlimid$76,285$526,23732 claims
Takeda Pharmaceuticals U.S.A., Inc.Iclusig$51,400$335,53816 claims
PfizerEliquis$248,742$25,63534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →